Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal prognosis. However, only a minority of patients exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkins, Michael B, Abu-Sbeih, Hamzah, Ascierto, Paolo A, Bishop, Michael R, Chen, Daniel S, Dhodapkar, Madhav, Emens, Leisha A, Ernstoff, Marc S, Ferris, Robert L, Greten, Tim F, Gulley, James L, Herbst, Roy S, Humphrey, Rachel W, Larkin, James, Margolin, Kim A, Mazzarella, Luca, Ramalingam, Suresh S, Regan, Meredith M, Rini, Brian I, Sznol, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528604/
https://www.ncbi.nlm.nih.gov/pubmed/36175037
http://dx.doi.org/10.1136/jitc-2022-005413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528604/
https://www.ncbi.nlm.nih.gov/pubmed/36175037
http://dx.doi.org/10.1136/jitc-2022-005413

Ejemplares similares